Author:
Moody William E.,Turvey-Haigh Lauren,Knight Daniel,Coats Caroline J.,Cooper Robert M.,Schofield Rebecca,Robinson Shaun,Harkness Allan,Oxborough David L.,Gillmore Julian D.,Whelan Carol,Augustine Daniel X.,Fontana Marianna,Steeds Richard P.
Abstract
AbstractThese guidelines form an update of the BSE guideline protocol for the assessment of restrictive cardiomyopathy (Knight et al. in Echo Res Prac, 2013). Since the original recommendations were conceived in 2013, there has been an exponential rise in the diagnosis of cardiac amyloidosis fuelled by increased clinician awareness, improvements in cardiovascular imaging as well as the availability of new and effective disease modifying therapies. The initial diagnosis of cardiac amyloidosis can be challenging and is often not clear-cut on the basis of echocardiography, which for most patients presenting with heart failure symptoms remains the first-line imaging test. The role of a specialist echocardiographer will be to raise the suspicion of cardiac amyloidosis when appropriate, but the formal diagnosis of amyloid sub-type invariably requires further downstream testing. This document seeks to provide a focused review of the literature on echocardiography in cardiac amyloidosis highlighting its important role in the diagnosis, prognosis and screening of at risk individuals, before concluding with a suggested minimum data set, for use as an aide memoire when reporting.
Publisher
Springer Science and Business Media LLC
Subject
Advanced and Specialized Nursing,Radiology, Nuclear Medicine and imaging,Radiological and Ultrasound Technology
Reference59 articles.
1. Knight D, Patel K, Whelan C, Steeds RP, Harkness A, Jones R, et al. A guideline protocol for the assessment of restrictive cardiomyopathy. Echo Res Prac. 2013. Available at: https://www.bsecho.org/common/Uploaded%20files/Education/Protocols%20and%20guidelines/Restrictive%20cardiomyopathy.pdf. Accessed 1 Jul 2023.
2. Gill SS, Felin E, Stampke L, Zhao Y, Masri A. Clinical clues and diagnostic workup of cardiac amyloidosis. Methodist DeBakey Cardiovasc J. 2022;18:36–46. https://doi.org/10.14797/mdcvj.1061.
3. Wechalekar AD, Fontana M, Quarta CC, Liedtke M. AL amyloidosis for cardiologists: awareness, diagnosis, and future prospects: JACC: cardiooncology state-of-the-art review. J Am Coll Cardiol CardioOnc. 2022;4:427–41. https://doi.org/10.1016/j.jaccao.2022.08.009.
4. Lousada IC, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32:920–8. https://doi.org/10.1007/s12325-015-0250-0.
5. Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140:16–26. https://doi.org/10.1161/CIRCULATIONAHA.118.038169.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献